"A better system" - managing the adverse effects of prescribed medicines: Cluster-randomised controlled trial and process evaluation of the ADRe Profile in primary care.

PLoS OneSep 18, 2026 (epub)

Vera Logan, Alex Conboy, Neil Carter et al.

✦ AI-curated · Sources linked

In 30 seconds

This cluster-randomized controlled trial evaluated the ADRe Profile's effectiveness in managing adverse drug reactions among patients aged ≥65 on multiple long-term medications in primary care. Conducted in South-West Wales, the study found that 82% of intervention patients had multiple problems addressed compared to 35% in the control group (adjusted odds ratio 7.48).

Key findings

  • 82% of intervention patients had multiple problems addressed compared to 35% in the control group.
  • All intervention patients either benefited or expected to benefit from referrals.
  • Fewer patients reported pain by the study's end (16/27 vs 24/27).

Why it matters

This study highlights the importance of systematic monitoring of prescribed medications in older adults, which can significantly reduce the risk of adverse drug reactions and improve patient outcomes in primary care settings.

Source

Published in PLoS One. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.